While PD-L1 is not uniformly overexpressed across all tumors, CXCL10 consistently exhibits elevated levels in tumors, particularly in lung, colon, and liver cancers, as a reliable biomarker for predicting immunotherapeutic efficacy [26]. This evidence concerns the gene CXCL10 and liver cancer.